Physician profile
Stephen Margulis
NPI 1689601486
$2,231.74
in general payments reported to CMS, 2019-2025
26 companies · $18.54 in 2025
The $18.54 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $173 · 2021: $121 · 2022: $503 · 2023: $612 · 2024: $82.05 · 2025: $18.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604.77 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.07 | 2019-2023 | Xifaxan, Plenvu |
| Janssen Scientific Affairs, LLC | $231.74 | 2019-2021 | |
| Qol Medical, LLC | $149.37 | 2019-2022 | |
| Janssen Biotech, INC. | $117.93 | 2019-2024 | Stelara |
| Celgene Corporation | $91.49 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $79.75 | 2019-2023 | Entyvio |
| Ferring Pharmaceuticals INC. | $68.01 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $63.75 | 2023-2024 | Idacio |
| Pfizer INC. | $60.54 | 2022-2023 | |
| Glaxosmithkline, LLC. | $52.02 | 2023-2025 | Shingrix, Arexvy |
| Intercept Pharmaceuticals, INC. | $43.57 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $41.96 | 2022-2023 | |
| Medtronic, INC. | $39.65 | 2023 | Minimed 780g |
| Ardelyx, INC. | $35.44 | 2022-2023 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34.28 | 2023 | Dupixent |
| Lilly USA, LLC | $32.40 | 2023 | Mounjaro |
| Novo Nordisk INC | $29.72 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $23.19 | 2019 | |
| Boston Scientific Corporation | $19.10 | 2019 | |
| Genzyme Corporation | $17.25 | 2022 | |
| Sanofi Pasteur INC. | $15.81 | 2023 | |
| Amarin Pharma, INC. | $13.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.72 | 2023 | Cyltezo |
| Dova Pharmaceuticals | $13.65 | 2019 | |
| Allergan, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Margulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.